Characteristics of the 108 patients
| Parameter . | Data . |
|---|---|
| No. men/no. women | 64/44 |
| Median age, y (range) | 33 (19-63) |
| B symptoms, yes/no, no. patients | 63/45 |
| Stage I/II, no. patients | 2/46 |
| Standard risk/high risk, no. patients | 32/4 |
| Stage III/IV, no. patients | 27/33 |
| Standard risk/high risk, no. patients | 24/35 |
| Score 0/1/2 points, no. patients | 3/13/40 |
| Score 3/4/5-7 points, no. patients | 27/5/7 |
| Parameter . | Data . |
|---|---|
| No. men/no. women | 64/44 |
| Median age, y (range) | 33 (19-63) |
| B symptoms, yes/no, no. patients | 63/45 |
| Stage I/II, no. patients | 2/46 |
| Standard risk/high risk, no. patients | 32/4 |
| Stage III/IV, no. patients | 27/33 |
| Standard risk/high risk, no. patients | 24/35 |
| Score 0/1/2 points, no. patients | 3/13/40 |
| Score 3/4/5-7 points, no. patients | 27/5/7 |
Pretherapy characteristics of patients with early unfavorable (n = 13) and advanced HD (n = 95) who were treated according to risk-stratified group, with interim reassessment.